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Background: Lipocalin-2 is a novel adipokine that appears to play a role in the development of insulin resistance.
Serum lipocalin-2 levels are elevated in obese patients. Obesity and insulin resistance are cardinal characteristics of
the polycystic ovary syndrome (PCOS). However, there are limited data on serum lipocalin-2 levels in patients with
PCOS. The aim of the present study was to assess serum lipocalin-2 levels in PCOS.
Methods: We studied 200 patients with PCOS and 50 healthy female volunteers.
Results: Serum lipocalin-2 levels were slightly higher in women with PCOS compared with controls (65.4 +/- 34.3
vs. 60.3 +/- 26.0 ng/ml, respectively) but this difference did not reach statistical significance. In contrast, lipocalin-2
levels were higher in overweight/obese women with PCOS than in normal weight women with the syndrome
(76.2 +/- 37.3 vs. 54.5 +/- 27.2 ng/ml, respectively; p < 0.001). Serum lipocalin-2 levels were also higher in
overweight/obese controls compared with normal weight controls (70.1 +/- 24.9 vs. 50.5 +/- 23.7 ng/ml,
respectively; p = 0.004). In the total study population (patients with PCOS and controls), lipocalin-2 levels were
independently correlated with the body mass index (p < 0.001). In women with PCOS, lipocalin-2 levels were
independently correlated with the waist (p < 0.001).
Conclusions: Obesity is associated with elevated serum lipocalin-2 levels. In contrast, PCOS does not appear to
affect lipocalin-2 levels.
Background
Polycystic ovary syndrome (PCOS) is characterized by
hyperandrogenism (biochemical hyperandrogenemia
and/or clinical manifestations of hyperandrogenemia),
chronic oligo- or anovulation and polycystic ovaries on
ultrasonography [1,2]. Obesity, usually of the central
type, is included in the cardinal characteristics of the
syndrome, as it is present in varying degrees (30-70%)
and is directly linked to increased peripheral insulin
resistance (IR) [3-5].
Insulin resistance, via the resulting hyperinsulinemia,
significantly contributes to the endocrine and metabolic
disturbances observed in PCOS [6,7]. Insulin has been
shown to stimulate theca cell androgen synthesis and
suppress sex hormone-binding globulin (SHBG) in the
liver, further increasing the free portion of circulating
androgens [8,9]. In addition, adiposity contributes to the
conversion of Δ4-androstendione (Δ4-A) to the most
potent androgen, testosterone (T), because adipocytes
have been shown to express significant amounts of the
enzyme 17b-hydroxysteroid dehydrogenase-ketosteroid
reductase [10,11].
Lipocalin-2 belongs to the superfamily of lipocalins and
was first isolated in human neutrophils. Lipocalin-2 is a
25 kDa glucoprotein that consists of 178 aminoacid resi-
dues and is covalently linked to metalloproteinases
[12,13]. The gene that encodes its synthesis is located on
chromosome 9 (9q34.11) and was characterized in 1997
[14]. Lipocalin-2 mRNA has been isolated in the bone
marrow, as well as in tissues exposed to microorganisms
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In addition, lipocalin-2 is expressed in several types of
cells, including adipocytes, endothelial cells, macro-
phages, vascular smooth muscle cells, hepatocytes, endo-
metrial cells and splenic cells [15-22].
Most investigators reported increased serum lipocalin-
2 levels in obese patients [23,24]. In addition, males
have higher serum lipocalin-2 levels and this gender dif-
ference is present in both normal weight and obese sub-
jects [23]. Moreover, lipocalin levels are elevated in
patients with cardiovascular diseases and might repre-
sent an independent cardiovascular risk factor [24].
Since a considerable proportion of patients with PCOS
has obesity (particularly abdominal), IR, glucose intoler-
ance, type 2 diabetes mellitus (T2DM) and low-grade
inflammation, i.e. disorders where lipocalin-2 secretion
is affected, the present study was designed to assess a)
serum lipocalin-2 levels in normal weight and
overweight/obese patients with PCOS, and, b) the asso-
ciation between serum lipocalin-2 levels and anthropo-




We studied 200 women with PCOS [age 24.5 ± 5.3
years, body mass index (BMI) 27.0 ± 6.4 kg/m
2]( G r o u p
I). We also studied 50 healthy women (age 32.6 ± 4.7
years, mean BMI 25.1 ± 4.0 kg/m
2)w i t hn o r m a lo v u l a t -
ing cycles (28 ± 2 days, blood progesterone levels >10
ng/ml in two consecutive cycles), no signs of hyperan-
drogenism and normal sonographic appearance of the
ovaries (control group, Group II)(Table 1). All women
with PCOS were outpatients at the Gynecological Endo-
crinology Infirmary of the Second Department of Obste-
trics and Gynecology, Aristotle University of
Thessaloniki, Greece, who had presented with at least
one of the following signs: oligomenorrhea, fertility pro-
blems, hirsutism, acne or male-pattern alopecia. Women
of the control group were healthy volunteers.
Diagnosis of PCOS was based on the revised criteria
of Rotterdam (see study protocol)[1,2]. None of the
women studied had galactorrhea or any endocrine or
systemic disease that could possibly affect reproductive
physiology. No woman reported use during the last
semester of any medication that could interfere with the
normal function of the hypothalamic-pituitary-gonadal
axis. When basic 17a-hydroxyprogesterone (17a-OHP)
levels were >1.5 ng/ml, the Synacthen test (0.25 mg/1
ml; Novartis Pharma S.A., Rueil-Malmaison, France) was
performed to rule out congenital adrenal hyperplasia.
Other causes of hyperandrogenemia, including prolacti-
noma, Cushing’s syndrome and androgen secreting
tumors were also excluded. Informed consent was
obtained from all women, and the study was approved
by the institutional review board. The study met the
requirements of the 1975 Helsinki guidelines.
Study protocol
In all women, body weight, height and waist circumfer-
ence (W) were measured. Body weight was measured
with analog scales and in light clothing; height was mea-
sured barefoot with a stadiometer. The BMI was calcu-
lated by dividing weight (in kg) by height squared (in m)
to assess obesity. The W was obtained as the smallest
circumference at the level of the umbilicus.
Baseline blood samples were collected between days 3
and 7 of the menstrual cycle in the control group and
between 3 to 7 days after a spontaneous bleeding epi-
sode in patients with PCOS, after an overnight fast. The
circulating levels of follicle-stimulating hormone (FSH),
luteinizing hormone (LH), prolactin (PRL), T, Δ4-A,
dehydroepiandrosterone sulfate (DHEA-S), 17a-OHP,
SHBG, glucose, insulin, thyroid stimulating hormone
(TSH) and free thyroxin (FT4) were measured. Immedi-
ately after the baseline blood sampling an oral glucose
tolerance test (OGTT) was performed; 75 g of glucose
were administered orally and serum glucose levels
were determined after 30, 60, 90 and 120 min. At the
same day transvaginal ultrasonography was performed
and the volume of each ovary was determined, as well
as the number of follicles in each ovary.
Patients with PCOS were divided according to BMI in
Subgroups Ia [BMI <25 kg/m
2; n = 100, age 23.4 ± 4.5
years, BMI 22.1 ± 1.8 kg/m
2] and Ib (BMI >27 kg/m
2;n
= 100, age 25.7 ± 5.8 years, BMI 31.9 ± 5.6 kg/m
2).
Controls were also divided according to BMI in sub-
groups IIa [BMI <25 kg/m
2; n = 25, age 31.3 ± 4.5
years, BMI 21.9 ± 1.6 kg/m
2]a n dI I b (BMI >27 kg/m
2;
n = 25, age 33.9 ± 4.6 years, BMI 28.3 ± 3.0 kg/m
2).
Methods
Plasma glucose, insulin, FSH, LH, PRL, androgens, 17a-
OHP, TSH and FT4 concentrations were measured as
previously described [25]. Serum lipocalin-2 levels were
determined with an enzyme-linked immunosorbent
assay (human lipocalin-2/NGAL Elisa, BioVendor Labor-
atorni medicina a.s., Modrice, Czech Republic). Lower
levels of detection was 0.02 ng/ml, the intra-assay coeffi-
cients of variation for low and high levels were 8.38 and
7.03%, respectively, and the inter-assay coefficients of
variation for low and high lipocalin-2 levels were 9.73
and 9.77%, respectively. Free androgen index (FAI) was
determined as follows: FAI = T (nmol/l) × 100/SHBG
(nmol/l) [26]. The homeostasis model assessment of IR
(HOMA-IR) index was calculated as follows: HOMA-IR
= fasting insulin (mIU/l) × glucose (mg/dl)/405 [27].
The quantitative insulin sensitivity check index
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mula: QUICKI = 1/[log Insulin (mIU/l) + log Glucose
(mg/dl))][28].
Transvaginal ultrasonography
Transvaginal ultrasonography was performed by an
experienced operator in all women. Ovarian volume was
calculated as follows: Ovarian volume = (π/6) × ovarian
length × ovarian height × ovarian width. Polycystic ovar-
ies were diagnosed when ≥ 12 follicles with a diameter
of 2-9 mm were present in one or both ovaries, or when
the ovarian volume was > 10 cm
3.
Statistical analysis
Data analysis was performed with the statistical package
SPSS (version 17.0; SPSS Inc., 233 South Wacker Drive,
11th Floor, Chicago, IL). All tested parameters followed
normal distribution as assessed with the Kolmogorov-
Smirnov test and are reported as mean ± SD. Because
women with PCOS were younger and had greater BMI
than controls (p <0.001 and p = 0.009, respectively),
comparisons between patients and controls were per-
formed with analysis of covariance (ANCOVA) adjusting
for age and BMI. Because normal weight women with
PCOS were younger than obese/overweight women with
PCOS (p = 0.002), comparisons between these groups
were performed with ANCOVA adjusting for age.
Because normal weight controls were younger than
obese/overweight controls (p = 0.046), comparisons
between these groups were performed with ANCOVA
adjusting for age. Changes between baseline and end-of-
treatment were assessed with the paired samples t-test.
Independent correlations between lipocalin-2 levels and
other parameters were assessed with stepwise linear
regression analysis including parameters that were sig-
nificantly correlated with lipocalin-2 levels in univariate
analysis. In all cases, a p value < 0.05 was considered
significant.
Results
The anthropometric, hormonal, metabolic and ultraso-
nographic features of women with PCOS and controls
are shown in Table 1. Women with PCOS had lower
plasma FSH levels and higher plasma T, Δ4-A, DHEA-S,
FAI and 17a-OHP levels than controls. In addition,
women with PCOS had greater mean ovarian volume
and a higher mean number of ovarian follicles than con-
trols. There were no differences in plasma glucose or
Table 1 Anthropometric, hormonal, metabolic and ultrasonographic characteristics of all patients with polycystic








(adjusted for age and BMI)
Age (years) 24.5 ± 5.3 32.6 ± 4.7 NA
BMI (kg/m
2) 27.0 ± 6.4 25.1 ± 4.0 NA
Waist (cm) 83.5 ± 14.9 80.8 ± 10.1 NS
FSH (mIU/ml) 6.4 ± 1.9 7.9 ± 2.8 0.007
LH (mIU/ml) 7.6 ± 5.0 5.9 ± 2.8 NS
Prolactin (ng/ml) 14.3 ± 6.9 12.2 ± 4.3 NS
Testosterone (ng/dl) 75.1 ± 30.1 32.9 ± 14.4 <0.001
Δ4-A (ng/ml) 2.9 ± 1.0 1.7 ± 0.5 <0.001
DHEA-S (ng/ml) 3106.0 ± 1300.8 1944.6 ± 811.8 <0.001
FAI 7.64 ± 6.1 1.98 ± 1.16 0.002
17a-OHP (ng/ml) 1.1 ± 0.5 0.7 ± 0.3 0.010
SHBG (nmol/l) 47.1 ± 28.1 69.2 ± 33.7 NS
Glucose (mg/dl) 98.5 ± 21.5 97.0 ± 9.8 NS
Insulin (μIU/ml) 12.4 ± 9.1 9.2 ± 6.8 NS
Glucose/insulin 11.52 ± 6.7 14.86 ± 9.03 NS
HOMA-IR 3.22 ± 3.90 2.24 ± 1.71 NS
QUICKI 0.34 ± 0.03 0.35 ± 0.03 NS
Area under the OGTT curve 15143.9 ± 3134.1 14565.6 ± 3352.5 NS
Mean ovarian volume (cm
3) 9.8 ± 4.9 5.3 ± 1.8 < 0.001
Mean number of ovarian follicles 10.8 ± 4.7 6.2 ± 1.9 < 0.001
Lipocalin (ng/ml) 65.4 ± 34.3 60.3 ± 26.0 NS
NA, not applicable; NS, not significant; BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone; Δ4-A, Δ4-androstenedione; DHEA-S,
dehydroepiandrosterone sulfate; FAI, free androgen index; 17a-OHP, 17a-hydroxyprogesterone; SHBG, sex hormone-binding globulin; OGTT, oral glucose
tolerance test; HOMA-IR, homeostasis model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index
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between women with PCOS and controls. Serum lipoca-
lin-2 levels were slightly higher in women with PCOS
compared with controls (65.4 ± 34.3 vs. 60.3 ± 26.0 ng/
ml, respectively) but this difference did not reach statis-
tical significance.
The anthropometric, hormonal, metabolic and ultraso-
nographic features of normal weight and overweight/
obese women with PCOS are shown in Table 2. Over-
weight/obese women with PCOS had greater BMI and
W than normal weight women with PCOS. Plasma
SHBG levels were lower and the FAI was higher in the
former. Moreover, plasma insulin levels, the area under
the OGTT curve and the HOMA-IR index were higher,
whereas the glucose/insulin ratio and the QUICKI were
l o w e ri no v e r w e i g h t / o b e s ew o m e nw i t hP C O St h a ni n
normal weight women with PCOS. Serum lipocalin-2
levels were also higher in overweight/obese women with
PCOS (76.2 ± 37.3 vs. 54.5 ± 27.2 ng/ml in normal
weight women with PCOS; p < 0.001).
The anthropometric, hormonal, metabolic and ultraso-
nographic features of normal weight and overweight/
obese controls are shown in Table 3. Overweight/obese
controls had greater BMI and W than normal weight
controls. Serum lipocalin-2 levels were also higher in
overweight/obese controls (70.1 ± 24.9 vs. 50.5 ± 23.7
ng/ml in normal weight controls; p = 0.004). In contrast,
there were no differences in hormone levels between the
two groups except plasma LH levels that were higher in
normal weight controls (p = 0.011). In addition, there
were no differences in plasma glucose and insulin levels,
the glucose/insulin ratio, the area under the OGTT
curve and the indices HOMA-IR and QUICKI between
normal weight controls and overweight/obese controls.
In the total sample of patients (n = 250), serum lipo-
calin-2 levels were negatively correlated with the
QUICKI (r = -0.221, p < 0.001), the glucose/insulin ratio
(r = -0.183, p = 0.004) and plasma SHBG levels (r =
-0.131, p = 0.039) and positively correlated with the
waist/hip ratio (r = 0.317, p < 0.001), W (r = 0.313, p <
0.001), BMI (r = 0.304, p < 0.001), HOMA-IR (r =
0.221, p < 0.001) and plasma insulin (r = 0.200, p =
0.002) and glucose levels (r = 0.191, p = 0.002). In step-
wise linear regression analysis, serum lipocalin-2 levels
were independently correlated with BMI (p < 0.001; Fig-
ure 1).
I nw o m e nw i t hP C O S( n=2 0 0 ), serum lipocalin-2
levels were negatively correlated with the QUICKI (r =
-0.265, p < 0.001), the glucose/insulin ratio (r = -0.245,
p < 0.001) and plasma SHBG levels (r = -0.152, p =
0.031) and positively correlated with the waist/hip ratio
Table 2 Anthropometric, hormonal, metabolic and ultrasonographic characteristics of normal weight and overweight/
obese patients with polycystic ovary syndrome (PCOS).
Group Ia
(normal weight patients with PCOS)
(n = 100)
Group Ib




Age (years) 23.4 ± 4.5 25.7 ± 5.8 NA
BMI (kg/m
2) 22.1 ± 1.8 31.9 ± 5.6 <0.001
Waist (cm) 72.8 ± 5.3 94.2 ± 13.6 <0.001
FSH (mIU/ml) 6.8 ± 1.9 6.0 ± 1.7 0.001
LH (mIU/ml) 8.5 ± 5.5 6.7 ± 4.4 0.025
Prolactin (ng/ml) 14.7 ± 6.6 13.9 ± 7.3 NS
Testosterone (ng/dl) 74.7 ± 27.3 75.4 ± 32.7 NS
Δ4-A (ng/ml) 2.9 ± 1.1 2.9 ± 0.9 NS
DHEA-S (ng/ml) 3148.6 ± 1218.2 3063.1 ± 1384.1 NS
FAI 5.80 ± 4.19 9.51 ± 7.19 <0.001
17a-OHP (ng/ml) 1.1 ± 0.5 1.1 ± 0.5 NS
SHBG (nmol/l) 59.0 ± 30.5 35.2 ± 19.4 <0.001
Glucose (mg/dl) 94.9 ± 10.0 102.1 ± 28.3 NS
Insulin (μIU/ml) 8.6 ± 5.0 16.1 ± 10.6 <0.001
Glucose/insulin 13.68 ± 6.02 9.36 ± 6.61 <0.001
HOMA-IR 2.04 ± 1.34 4.38 ± 5.08 <0.001
QUICKI 0.35 ± 0.03 0.32 ± 0.03 <0.001
Area under the OGTT curve 14496.9 ± 2725.9 15797.4 ± 3388.2 0.006
Mean ovarian volume (cm
3) 7.7 ± 3.7 11.9 ± 5.0 <0.001
Mean number of ovarian follicles 10.9 ± 5.2 10.8 ± 4.1 NS
Lipocalin (ng/ml) 54.5 ± 27.2 76.2 ± 37.3 <0.001
Abbreviations are defined in Table 1.
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(r = 0.314, p < 0.001), HOMA-IR (r = 0.265, p < 0.001)
and plasma insulin (r = 0.254, p < 0.001) and glucose
levels (r = 0.162, p = 0.002). In stepwise linear regres-
sion analysis, serum lipocalin-2 levels were indepen-
dently correlated with the W (p < 0.001; Figure 2).
Discussion
Lipocalins are bioactive peptides that belong to adipokines.
The lipocalin superfamily includes more than 20 small
extracellular peptides that exert multiple functions mostly
after binding to other molecules [29]. They were named
lipocalins by Pervaiz and Brew from the Greek words
“lipos” (i.e. fat) and “kalyx” (i.e. cup), because of their cup-
like molecule [30,31]. Lipocalin-2 has a similar tertiary
structure with other lipocalins and its pivotal characteristic
is the presence of a hydrophobic calyx that binds to small
lipophilic molecules. The main binding part of lipocalin-2
is its small iron-binding molecules [29]. Accordingly, lipo-
calin-2 both binds and transfers iron, an essential










Age (years) 31.3 ± 4.5 33.9 ± 4.6 NA
BMI (kg/m
2) 21.9 ± 1.6 28.3 ± 3.0 <0.001
Waist (cm) 73.7 ± 5.6 87.9 ± 8.5 <0.001
FSH (mIU/ml) 8.1 ± 2.5 7.8 ± 3.2 NS
LH (mIU/ml) 7.1 ± 3.3 4.8 ± 1.5 0.011
Prolactin (ng/ml) 12.1 ± 3.8 12.4 ± 4.7 NS
Testosterone (ng/dl) 36.4 ± 14.5 29.4 ± 13.8 NS
Δ4-A (ng/ml) 1.8 ± 0.4 1.7 ± 0.6 NS
DHEA-S (ng/ml) 2138.9 ± 788.6 1750.4 ± 803.1 NS
FAI 1.89 ± 0.99 2.07 ± 1.31 NS
17a-OHP (ng/ml) 0.7 ± 0.3 0.7 ± 0.3 NS
SHBG (nmol/l) 76.4 ± 30.8 61.9 ± 35.5 NS
Glucose (mg/dl) 95.1 ± 7.8 98.9 ± 11.2 NS
Insulin (μIU/ml) 8.2 ± 7.0 10.3 ± 6.6 NS
Glucose/insulin 15.48 ± 7.27 14.23 ± 10.62 NS
HOMA-IR 1.96 ± 1.76 2.53 ± 1.63 NS
QUICKI 0.36 ± 0.03 0.35 ± 0.04 NS
Area under the OGTT curve 13009.8 ± 1680.8 16121.4 ± 3883.3 0.002
Mean ovarian volume (cm
3) 5.3 ± 1.9 5.3 ± 1.8 NS
Mean number of ovarian follicles 6.0 ± 1.9 6.4 ± 1.9 NS
Lipocalin (ng/ml) 50.5 ± 23.7 70.1 ± 24.9 0.004
Abbreviations are defined in Table 1.
Figure 1 Correlation of serum lipocalin-2 levels with the body
mass index in the total study population (Groups 1 and 2, n =
250).
Figure 2 Correlation of serum lipocalin-2 levels with the waist
in women with PCOS (Group 1, n = 200).
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fore, lipocalin-2 exerts bacteriostatic actions and appears
to play an important role in innate immunity and immune
response to bacterial infections [32-35].
In the present study, serum lipocalin-2 levels were
marginally higher in women with PCOS compared with
controls (65.4 ± 34.3 vs. 60.3 ± 26.0 ng/ml, respectively)
b u tt h i sd i f f e r e n c ed i dn o tr e ach significance (Table 1).
Plasma glucose or insulin levels, the glucose/insulin
ratio, the area under the OGTT curve and the indices
HOMA-IR and QUICKI also did not differ between
women with PCOS and controls. The lack of difference
in insulin resistance between patients with PCOS and
controls might be partly due to the inclusion of patients
with the ovulatory phenotype of PCOS, which is known
to have a milder form of the metabolic disturbances
[36]; among the 200 patients with PCOS, 50 (25%) had
this phenotype. In addition, we used relatively insensi-
tive markers of insulin resistance (i.e. the HOMA-IR
and QUICKI indices) instead of the gold standard eugly-
cemic hyperinsulinemic clamp and this might have also
precluded the detection of a difference in insulin resis-
tance between patients with PCOS and controls [37,38].
The slightly higher serum lipocalin-2 levels in women
with PCOS (Group I) compared with controls (Group
II) might be due to the greater BMI in the former
(Table 1), since serum lipocalin-2 levels are elevated in
obese patients [23,24]. However, the present study sug-
gests that PCOS does not affect serum lipocalin-2 levels.
Overweight/obese women with PCOS (subgroup Ib)
had higher serum lipocalin-2 levels than normal weight
women with PCOS (subgroup Ia)(p < 0.001; Table 2).
Similarly, overweight/obese controls (subgroup IIb)h a d
higher serum lipocalin-2 levels than normal weight con-
trols (subgroup IIa)(p = 0.004; Table 3). In the total
study population (n = 250), in stepwise linear regression
analysis, serum lipocalin-2 levels were independently
correlated with BMI (p < 0.001; Figure 1). Moreover, in
women with PCOS (n = 200), in stepwise linear regres-
sion analysis, serum lipocalin-2 levels were indepen-
dently correlated with W (p < 0.001; Figure 2). A
significant increase in serum lipocalin-2 levels has been
previously reported in obese patients [23,24]. In addi-
tion, the elevated serum lipocalin-2 levels in obese
patients correlate with anthropometric, hormonal and
metabolic parameters [23]. Moreover, the strong corre-
lation between serum lipocalin-2 levels and both the
HOMA-IR index and plasma glucose levels, which is
not affected after adjusting for the BMI, suggests that
lipocalin-2 might represent an independent risk factor
for development of IR and hyperglycemia.
There are only two studies that assessed serum lipoca-
lin-2 levels in patients with PCOS [39,40]. However,
these two studies yielded conflicting results. In the first
study, serum lipocalin-2 levels were determined in 40
patients with PCOS and 40 controls, aged 25.4 ± 4.5
and 27.4 ± 4.4 years, respectively, and with BMI of 25.3
± 3.8 and 23.4 ± 2.4 kg/m
2, respectively [39]. The matrix
metalloproteinase-9 (MMP-9)/neutrophil gelatinase-
associated lipocalin (NGAL) complex was also mea-
sured. Serum lipocalin-2 and MMP-9/NGAL complex
levels were lower in patients with PCOS than in controls
(p < 0.001 for both comparisons)[39]. The investigators
suggested that NGAL and MMP-9/NGAL complex
levels should be further evaluated in patients with
PCOS, because the decreased levels of these atherogenic
molecules might protect patients with PCOS against
cardiovascular disease (CVD). In the second study,
serum lipocalin-2 levels were measured in 30 patients
with PCOS and 30 controls [40]. Receiver operating
characteristic curves were plotted to determine the
serum levels of lipocalin-2 that indicate the presence of
IR. This study showed that lipocalin-2 levels are elevated
in patients with PCOS compared with controls (p <
0.001) and that lipocalin-2 may prove to be a useful
marker of IR in patients with PCOS [40]. In the present
study we evaluated a substantially larger number of
patients with PCOS (n = 200) and we did not observe
significant differences in serum lipocalin-2 levels
between patients with PCOS and controls (Table 1).
However, overweight/obese patients with PCOS and
overweight/obese controls had significantly higher lipo-
calin-2 levels than normal weight patients with PCOS
and normal weight controls, respectively (p < 0.001 and
p = 0.004, respectively; Table 2 and 3).
It has been reported that serum lipocalin-2 levels are
elevated in patients with CVD and might represent an
independent cardiovascular risk factor [24]. It has also
been reported that gelatinase B (also known as MMP-9),
an endopeptidase capable of degrading the molecular
components of the extracellular matrix, is associated with
increased risk for abdominal aortic aneurysm, athero-
sclerosis and plaque rupture [41,42]. Therefore, MMP-9 is
considered to be an important mediator of vascular remo-
deling and plaque instability [43]. Physical disruption of
the atherosclerotic plaque triggers thrombus formation,
which might lead to myocardial infarction (MI). MMP-9
action is enhanced by NGAL, also known as lipocalin-2
[44]. The formation of the MMP-9/lipocalin-2 complex is
crucial for atherotic plaque erosion and thrombus forma-
tion [19,45,46]. Hemdahl et al have shown increased
expression of lipocalin-2 and co-localization with MMP-9
in atherosclerotic plaques and MI lesions [47].
Conclusions
Our findings suggest that PCOS is not associated with
significant changes in serum lipocalin-2 levels. On the
other hand, obese patients have elevated serum
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The increased serum lipocalin-2 levels in overweight
and obese patients with PCOS potentially represent a
useful marker of IR.
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